Clinical trials: Endometrial Cancer Recurrent
- Condition Endometrial Cancer Recurrent
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or…
- Trial name
- NCT03077698
- Testing
- Sodium Cridanimod, progestin therapy
- Where
- 25 sites in United States
- Volunteers
- 25 people
- Sponsor
- Xenetic Biosciences, Inc.
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Endometrial Cancer Recurrent
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.
- Trial name
- NCT03485729
- Testing
- Dordaviprone (ONC201)
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Endometrial Neoplasms
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
- Trial name
- NCT01420081
- Testing
- PF-05212384
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Pfizer
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT03884101)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 195 sites in United States, Argentina and 20 more
- Volunteers
- 842 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT04865289)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 22 sites in China
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Neoplasms by Site
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced…
- Conditions
- Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00377520
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Endometrial Cancer
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
- Trial name
- ZoptEC (NCT01767155)
- Testing
- AEZS-108 / zoptarelin doxorubicin, doxorubicin
- Where
- 123 sites in United States, Austria and 20 more
- Volunteers
- 511 people
- Sponsor
- AEterna Zentaris
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Endometrial Cancer
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
- Trial name
- NCT00910091
- Testing
- BN83495, Megestrol Acetate (MA)
- Where
- 54 sites in Belgium, Czechia and 10 more
- Volunteers
- 73 people
- Sponsor
- Ipsen
Endometrial Neoplasms
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
- Trial name
- NCT02725268
- Testing
- Paclitaxel, Sapanisertib, MLN1117
- Where
- 78 sites in United States, Australia and 8 more
- Volunteers
- 241 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms, Endometrial, Endometrial Cancer
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
- Trial name
- NCT00267488
- Testing
- topotecan
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Endometrial Carcinoma
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
- Trial name
- NCT00334295
- Testing
- Fulvestrant
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Endometrial Neoplasms
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed…
- Trial name
- DUO-E (NCT04269200)
- Testing
- olaparib, durvalumab, Carboplatin
- Where
- 201 sites in United States, Australia and 20 more
- Volunteers
- 805 people
- Sponsor
- AstraZeneca
Endometrial Cancer, Uterine Cancer
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
- Conditions
- Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
- Trial name
- P204 (NCT03395080)
- Testing
- Paclitaxel, 300mg DKN-01, 600mg DKN-01
- Where
- 17 sites in United States
- Volunteers
- 111 people
- Sponsor
- Leap Therapeutics, Inc.
Endometrial Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or…
- Trial name
- IXAMPLE2 (NCT00883116)
- Testing
- Ixabepilone, Doxorubicin, Paclitaxel
- Where
- 93 sites in United States, Argentina and 17 more
- Volunteers
- 551 people
- Sponsor
- R-Pharm
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Endometrial Cancer
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
- Trial name
- NCT04205630
- Testing
- SYD985
- Where
- 36 sites in United States, Poland and 5 more
- Volunteers
- 64 people
- Sponsor
- Byondis B.V.